KPA protesting the description of oriental medicine in specific drugs

The Korea Food and Drug Administration (KFDA) has intended to newly add the following regulation in the rules on the review of application for manufacture or import of drugs and quasi-drug (Paragraph 2, Article 7; brandname), to the effect that in the case of an oriental medicine, the brandname should indicate "oriental medicine" in parenthesis.

During its consultation with related organiza...